Several commercially available pharmaceutical compounds have been shown to block the I Kr current of the cardiac action potential. This effect can cause a prolongation of the electrocardiogram QT interval and a delay in ventricular repolarization. The Food and Drug Administration recommends that all new potential drug candidates be assessed for I Kr block to avoid a potentially lethal cardiac arrhythmia known as torsades de pointes. Direct compound interaction with the human ether-a-go-gorelated gene (hERG) product, a delayed rectifier potassium channel, has been identified as a molecular mechanism of I Kr block. One strategy to identify compounds with hERG liability is to monitor hERG current inhibition using electrophysiology techniques. The authors describe the IonWorks HT ™ instrument as a tool for screening cell lines expressing hERG channels. Based on current amplitude and stability criteria, a cell line was selected and used to perform a 300-compound screen. The screen was able to identify compounds with hERG activity within projects that spanned different therapeutic areas. The cell line selection and optimization, as well as the screening abilities of the IonWorks HT ™ system, provide a powerful means of assessing hERG active compounds early in the drug discovery pipeline. (Journal of Biomolecular Screening 2005:832-840) 
INTRODUCTION

I
ON CHANNELS REPRESENT a relatively small class of pharmaceutical targets, partly as a result of historical limitations in the development of ion channel screening assays. Now, with advances in electrophysiology technologies, 1, 2 there is renewed interest in these proteins as targets for drug discovery. A number of ion channels have been linked to inherited diseases, and as a result, ion channels are now being considered for the treatment and prevention of disease. 3 One of the most important ion channels being studied in the pharmaceutical industry has not been used as a target but rather has become an issue within safety pharmacology. The voltage-gated human ether-a-go-go-related gene (hERG) potassium channel contributes to the rapidly activating delayed rectifier potassium current (I Kr ) of the cardiac action potential. Drug interaction with the hERG channel is one of the mechanisms that can lead to the electrocardiogram QT interval prolongation and the potential for a cardiac arrhythmia known as torsades de pointes (TdP). 4 This side effect can be fatal, and this risk has led to many pharmaceutical products being withdrawn from the market. More than 50 drugs on the market for noncardiovascular therapeutic indications have been reported to cause QT prolongation, and some have the ability to induce TdP. 5 The Food and Drug Administration (FDA) and other regulatory bodies recommend that all potential drug candidates be assessed for the ability to cause QT prolongation.
Predicting QT prolongation by preclinical in vitro methods is noted in the International Conference on Harmonization (ICH) S7B guidelines. 6 In these draft guidelines, electrophysiology is recommended as the preferred approach to study compounds that inhibit hERG current. hERG data are typically used with other data sets (i.e., maximal free plasma binding, free C max ) as an integrative approach to derisking compounds for cardiovascular safety. Combining preclinical data from various assays can generate safety margins that assist in developing strategies to move compounds forward. 7 Given the current costs associated with bringing a drug to market, 8 it can be financially devastating to discover hERG liability of a compound in the later stages of the drug discovery pipeline. One approach is to screen for this liability early in the drug development process, but the standard patch-clamp assay is very technically demanding, requires highly skilled individuals, and is low throughput. High-throughput (HT) electrophysiology methods maintain most of the information content of standard patch-clamp techniques and may ultimately provide the throughput and flexibility of other similar screening devices, which have enabled targets such as G-protein-coupled receptors (GPCRs) to be well studied.
Here, we describe data collected from the IonWorks HT ™ planar patch system, which is used within the pharmaceutical industry for both ion channel screening and safety assessment. 9, 10 To use the planar patch technology successfully, cell lines need to be optimized for peak performance. The process of visually selecting "patchable" cells through the microscope of a standard electrophysiology setup is not possible with the planar patch technologies. New challenges have arisen with the requirement to produce highly robust cell culture populations that express the ion channel of interest, are capable of forming good seals, and endure long-lasting, stable electrophysiological recordings.
The IonWorks HT ™ system was used to identify hERGexpressing cell lines that reproducibly formed stable seals with the PatchPlate ™ planar array substrate and that generated large-current amplitudes. Once a cell line was established as a good candidate for planar patch electrophysiology recordings on the IonWorks HT ™ system, a single-point 300-compound screen was carried out to identify compounds that exhibited > 50% hERG current inhibition at 30 µM. Subsequently, the "hits" were rescreened, and hERG IC 50 values were determined. Ultimately, the IonWorks HT ™ system produced hERG IC 50 values that were representative of standard patch-clamp electrophysiology.
METHODS
IonWorks HT
™
Cell culture
Chinese hamster ovary (CHO) and human embryonic kidney (HEK) cells were used as either parental cell lines or as stable cell lines expressing hERG. Three cell lines were from confidential external sources. The remaining cell lines were generated at Roche; details regarding their construction are discussed below. Tissue culture flasks used were T-75 (Falcon, cat. BD 353136). Cell culture media components included Ham's F-12 (Gibco, cat. 8061799), alpha minimum essential medium (MEM) with ribonucleosides and L-glutamine (Gibco, cat. 12571-048), MEM (Gibco, cat. 11090-081), Dulbecco's modified Eagle's medium (DMEM, Gibco, cat. 11965-084), DMEM with high glucose (Gibco, cat. 11956-084), fetal bovine serum (FBS, Gibco, cat. 16140-089), L-glutamine (Gibco, cat. 25030-081), penicillin/ streptomycin (P/S, Gibco, cat. 15140-122), geneticin (G-418, Gibco, cat. 10131-035), and hygromycin (Invitrogen, cat. 10687-010). Disassociation media included Versene ™ (Gibco, cat. 15040-066) or trypsin (Gibco, cat. 25200-056).
Roche hERG cell lines
A CHO-K1 cell clone with loxP sites 11 marking a highly expressing and stable chromosomal locus was generated. Briefly, CHO-K1 cells were transfected with a plasmid in which a cytomegalovirus (CMV) promoter drives expression of an mRNA encoding a blue fluorescence protein-internal ribosome entry site (IRES)-hygromycin selection marker cassette. The cassette also contains 2 nonidentical loxP sites, 1 in between the CMV promoter and the 5′ end of the fluorescence protein open reading frame (ORF) and the other at the 3′ end of the hygromycin selection marker. A CHO cell clone with high levels of blue fluorescence protein expression that remained stable over multiple generations was obtained and its nature as a single-locus integrant verified by genomic DNA blotting. Site-specific recombination of a hERG-IRES 12 -neomycin resistance marker cassette flanked with the same loxP sites as described above into this loxP-marked recipient cell line was subsequently achieved via short-term transient cotransfection of a plasmid expressing the CRE recombinase.
11
CHO cell colonies selected in 1 mg/mL geneticin were visually scanned for the absence of blue fluorescence, indicating the removal of the blue fluorescence protein coding region by the CREmediated recombination event. After ring cloning and expansion, recombination-mediated removal of the hygromycin resistance marker in these cells was demonstrated by testing their sensitivity to hygromycin. Correct site-specific integration of the hERG-ORF downstream of the CMV promoter was finally ascertained by genomic DNA PCR. Sixteen cell clones fulfilling these criteria were isolated from an initial transfection of 5 million cells, scaled up, and analyzed for expression of hERG protein by Western blot and hERG ion channel function on the IonWorks HT ™ instrument.
Guava personal cell analyzer
The Guava personal cell analyzer (PCA) was used to determine viable cell count. The ViaCount assay uses Guava ViaCount Reagent containing fluorescent DNA binding dyes, which distinguish viable and nonviable cells based on cell permeability of the dyes. Cells were removed from flasks with disassociation media, diluted 10-fold in Guava ViaCount Reagent (Guava Technologies, Inc., cat. 4000-0040), and incubated 5 min at room temperature. Data output included number of viable cells/mL and percent viability.
Perforation agent
The IonWorks HT ™ platform uses the perforated patch technique to gain electrical access to the inside of a cell. Perforation agent was made fresh prior to each experiment. Dimethyl sulfoxide (DMSO; J. T. Baker, cat. 9224-01) was added (180 µL) to 5 mg of amphotericin B (Sigma, cat. A-4888), vortexed until clear (~2 min), added to 50 mL of internal buffer, and then vortexed for~20 sec.
3143-01). The external buffer was phosphate-buffered saline (PBS; Gibco, cat. 14040).
Cell preparation
CHO cells expressing hERG were grown in HAM's F-12 or 1:1 HAM's F-12/DMEM or alpha MEM media supplemented with 10% FBS, 1% P/S, and 0.5 mg/mL G-418. The parental CHO cell line was cultured in the absence of G-418. HEK cells expressing hERG were grown in MEM or DMEM with 10% FBS, 1% P/S, and 0.5 mg/mL G-418. The parental HEK cell line was cultured in DMEM with high glucose in the absence of G-418, supplemented with L-glutamine. Cells were plated at an approximate density of 1 to 3 × 10 6 cells/mL and passaged at regular intervals when the flasks reached 80% to 100% confluence. Cells were prepared for experiments by splitting at 1:4 to 1:10 two or three days prior to use.
In preparation for experiments, media were removed from the culture flasks; cells were rinsed with 4 mL trypsin and then incubated with 4 mL of trypsin for 4 min at 37°C. Trypsin was preferred over Versene ™ because cells disassociated easier, although 1 report indicated better seal resistances when Versene ™ was used. 13 Then, 20 mL PBS was added to the flask, and the cell suspension was centrifuged at low gravity. Supernatant was removed, and 3 mL PBS was added per tube and triturated. The cell suspension was added to the cell boat on the IonWorks HT ™ instrument just prior to the beginning of the experiment.
Western blot
Whole-cell lysates were prepared; 50,000 cells per lane were run on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred via electrophoresis to nitrocellulose membranes, and probed with anti-hERG antibody (Alomone Labs, cat. APC-062). Whole-cell hERG expression was detected using an ECL detection kit (Amersham Biosciences, cat. RPN 2108).
Compound plate
Stock solutions of compounds (10 mM in 100% DMSO) were diluted to testing concentrations in PBS and further diluted 3-fold in PBS on the IonWorks HT ™ system. Final DMSO concentrations were less than 0.3%. The positive control was haloperidol (Sigma, H-1512); the negative control was 0.1% DMSO in PBS. Compound plates used were 96-well format (Falcon, cat. 351190).
Patch substrate
PatchPlate ™ substrates were distributed by Molecular Devices (cat. 9000-0688).
Electrophysiology
The IonWorks HT ™ system voltage clamps and records a subset of cells at one time. Cells are first tested for seal formation to the patch substrate, and then pre-and postdrug recordings are made. Currents are recorded from 48 cells simultaneously via the electronics head (e-head; analogous to the head stage of a standard patch-clamp amplifier). During pre-and postdrug recordings, cells were voltage-clamped with a resting potential of -80 mV. hERG currents were elicited by depolarizing the cell to a +40-mV prepulse (500 msec) and then hyperpolarizing to a -40-mV test pulse (500 msec), as depicted in Figure 1 . Leak current was determined at the holding potential (-80 mV) and applied in a linear proportion to all other clamped potentials studied. Compounds were applied for 5 min, during which time the cells were unclamped. The e-head must be removed from the PatchPlate ™ wells for liquid handling. hERG current recordings were elicited by the voltage pulse protocol described in Figure 1 and measured after the 5-min compound incubation period, when cells were reclamped for determination of hERG current inhibition. 
Standard patch clamp
Cell culture hERG currents were measured using a stable HEK cell line expressing hERG by whole-cell patch-clamp configuration. 
IC 50 curve generation and statistics
Concentration-response curves were fit in Origin (version 6) as the mean percent blockade (± SEM) at concentrations tested.
RESULTS
Cell line assessment
The IonWorks HT ™ system is an excellent tool to functionally and systematically assess many different stably transfected voltage-gated ion channel cell lines. Twenty-three distinct cell lines were evaluated for the ability to perform on the IonWorks HT ™ platform. The hERG currents expressed in CHO or HEK cells were elicited by the perforated patch-clamp technique using a standard hERG voltage pulse protocol (Fig. 1) . Current amplitude was measured at the end of the test pulse (500 msec at -40 mV) and reported after a linear leak subtraction (see Methods).
We chose to use 4 parameters to assess the quality of the cell lines: seal success rates, seal resistance, current amplitude, and current stability. Experiments were carried out to identify cell lines that exhibited high numbers of seals and high seal resistances. High seal rates indicate that a cell line can be adapted to record from the PatchPlate ™ substrate, and high seal resistances allow better recording quality, as there is less leak current. Twenty cell lines expressing hERG in CHO cells, 1 cell line expressing hERG in HEK cells, and parental (nontransfected) CHO cells and HEK cells were included in the evaluation. Seal success rates and seal resistances were measured on the 23 cell lines (Fig. 2) . Seal success was defined as a cell within a PatchPlate ™ well that exhibited a resistance > 20 MOhm. Seal success is a binary measure; it does not suggest anything about the quality of a seal and is merely an indicator of an elevated resistance compared with the native hole resistance of 3 MOhm (analogous to pipette tip resistance). Resistance of the seal in standard perforated patch-clamp experiments can exceed 1 GOhm, but with the solutions used during these experiments, most cell lines were recorded from after achieving 50 to 250 MOhm seals (Fig. 2) . Since this study was completed, GOhm seal formation with the IonWorks HT ™ system has been reported. 14 Seal rate indicated no significant difference between the cell lines, but there was variation in seal resistance (Fig. 2) . Note that some cell lines were tested on multiple runs. We assessed the cell lines for current amplitude, as well as the stability of the current, before, and after the drug additions. Current stability was defined as positive or negative changes in the current amplitude after a cell had been unclamped for a period of 5 min (Fig. 3) . Typically, 4 cell lines were run per PatchPlate ™ experiment (384 wells), allowing information from 96 wells for each cell line to be used to determine the measured parameters. Figure 4 demonstrates differences in the stability (top panel) of the cell lines and the current amplitude (bottom panel). When assessing current amplitude, current stability, seal success rates, and seal resistances, correlation was only significant between current amplitude and stability (Pearson r = 0.7356, p < 0.0001, R 2 = 0.5412). From this information, a cell line (CHO-hERG #6) generated at Roche (see Methods) was isolated and monitored over 2 months on the IonWorks HT ™ system. In addition to automated electrophysiology, techniques used to evaluate ion channel cell lines include binding studies, flux assays, and Western blots. Binding assays are nonfunctional, and flux assays are indirect end-point assays. Here we used Western blots with whole-cell lysates as a complementary assay to the IonWorks 
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™ system and observed that measurements of protein expression did not correlate with functional data. For example, in Figure  5 , lane 15 indicates low levels of whole-cell hERG protein expression; however, whole-cell patch-clamp recordings with this cell line exhibited current amplitude well over 1 nA (data not shown). One explanation of this discrepancy is that Western blots are subject to the sensitivity of the antibody. In conclusion, results obtained with Western blots were inconsistent and not as direct as the functional results reported by the IonWorks HT ™ system. A better assessment of ion channel expression correlating to functional expression may have been elucidated with Western blots using cell membrane fractions. The IonWorks HT ™ system was used in conjunction with the Guava PCA to monitor the viability of the candidate cell line selected for screening (CHO-hERG #6). Figure 6 shows a direct correlation between cell viability and the overall success rate observed on the IonWorks HT ™ system. Cells considered successful were those that had a seal resistance > 50 MOhm, had a current amplitude > 200 pA, and, during control experiments, had a current amplitude that did not increase or decrease more than 20%. Cell viability correlates with percentage of success (Pearson r = 0.9273, p < 0.0001, R 2 = 0.8600) and percentage of seal success (Pearson r = 0.6553, p < 0.04, R 2 = 0.4294). The Guava PCA allows a prediction of the achievable overall success rate of a screen on any given day by assessing viability and thus provides an additional tool that can be valuable when setting up a screen.
hERG screen and concentration-response analysis
From the initial cell line evaluation, a cell line (CHO-hERG #6) exhibiting an average current amplitude of 800 pA, > 80% seal rate success, seals between 100 and 200 MOhm, and 80% overall successful recordings was chosen to be used in the compound library screen (Figs. 2 and 4 ). We commenced with having a screen of 300 compounds to find those compounds that inhibited ≥ 50% of hERG current after a 30-µM drug application. Compounds from several projects were used for the screen, some of which were already known to block hERG channels when studied by standard patch clamp, although the experiments here were performed blinded. Three drug plates were prepared on 96-well plates, and each was run twice, with approximately 90 compounds per plate (each compound was tested 4 times). Using the 384-well PatchPlate ™ , the 300-compound single-point screen was completed in one 8-h day (Fig. 7) . One run using a compound plate took approximately 40 min. In total, each compound was used in 8 PatchPlate ™ wells, generally allowing between 3 and 8 successful cells (data points) at the 1 concentration.
During the screen, 8 PatchPlate ™ wells were used by screening each compound concentration twice to ensure a sufficient number of cells per data point. The redundancy of 8 wells was necessary because of the variability in success rate. Thus, it is possible to have a range in n values from 1 to 8 for each compound. Replicate PatchPlate ™ wells are also important because of cell-to-cell variability within a cell line. Figure 8 shows variability observed with the CHO-hERG #6 cell line over 9 experimental days (nonconsecutive). During this time, after the initial cell line evaluation, this cell line produced an average current amplitude of 650 pA, which was reduced from the 800 pA observed in the cell line evaluation phase of this study. Current stability was high and approached 90% (Fig. 9) . Although replicates used in these experiments may have increased our screening time, sufficient data were produced within the screening time designated. With the new IonWorks Quattro, a technology incorporating Population Patch Clamp ™ technology (increased number of recording holes in the PatchPlate ™ well), the redundancy practiced here will be eliminated. 
